BiotechTube

dupilumab + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Atopic Hand and Foot Dermatitis

Conditions

Moderate to Severe Atopic Hand and Foot Dermatitis

Trial Timeline

Apr 14, 2021 → Nov 23, 2022

NCT ID
NCT04417894

About dupilumab + Placebo

dupilumab + Placebo is a phase 3 stage product being developed by Sanofi for Moderate to Severe Atopic Hand and Foot Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04417894. Target conditions include Moderate to Severe Atopic Hand and Foot Dermatitis.

What happened to similar drugs?

18 of 20 similar drugs in Moderate to Severe Atopic Hand and Foot Dermatitis were approved

Approved (18) Terminated (4) Active (2)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
✅Risankizumab + DeucravacitinibAbbVieApproved
✅adalimumabAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT07053423ApprovedRecruiting
NCT06687967Phase 3Active
NCT06687980Phase 3Active
NCT06191315Phase 3Recruiting
NCT06101095ApprovedActive
NCT05731128Phase 2Active
NCT05097287ApprovedRecruiting
NCT04988022ApprovedCompleted
NCT04417894Phase 3Completed
NCT04442269Phase 2Completed
NCT04512339Phase 2UNKNOWN
NCT04400318ApprovedCompleted
NCT04033367ApprovedCompleted
NCT03749148Phase 2Completed
NCT03749135Phase 2Completed
NCT03633617Phase 3Completed
NCT03389893ApprovedTerminated
NCT03359356Phase 2Completed
NCT03054428Phase 3Completed
NCT02379052Phase 2Completed

Competing Products

20 competing products in Moderate to Severe Atopic Hand and Foot Dermatitis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
PexidartinibDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
Ranirestat + PlaceboEisaiPhase 2/3
38
E6007 + PlaceboEisaiPhase 2
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
35
KHK4827 + PlaceboKyowa KirinPhase 2
35
Stelara + Bmab1200BioconPhase 3
40